Kohjin Bio Co., Ltd. Share Price

Equities

177A

JP3283630006

Pharmaceuticals

Market Closed - Japan Exchange 07:00:00 28/06/2024 BST 5-day change 1st Jan Change
1,938 JPY -4.95% Intraday chart for Kohjin Bio Co., Ltd. +5.73% 0.00%

Financials

Sales 2025 * 4.72B 29.31M 2.32B Sales 2026 * 5.13B 31.87M 2.52B Capitalization 9.72B 60.38M 4.78B
Net income 2025 * 618M 3.84M 304M Net income 2026 * 671M 4.17M 330M EV / Sales 2025 * 2.06 x
Net cash position 2025 * - 0 0 Net cash position 2026 * - 0 0 EV / Sales 2026 * 1.89 x
P/E ratio 2025 *
15.6 x
P/E ratio 2026 *
14.5 x
Employees -
Yield 2025 *
0.72%
Yield 2026 *
0.72%
Free-Float 27.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.95%
1 week+5.73%
Current month+9.06%
1 month+5.56%
More quotes
1 week
1 800.00
Extreme 1800
2 220.00
1 month
1 635.00
Extreme 1635
2 220.00
Current year
1 466.00
Extreme 1466
2 375.00
1 year
1 466.00
Extreme 1466
2 375.00
3 years
1 466.00
Extreme 1466
2 375.00
5 years
1 466.00
Extreme 1466
2 375.00
10 years
1 466.00
Extreme 1466
2 375.00
More quotes
Date Price Change Volume
28/06/24 1,938 -4.95% 83,800
27/06/24 2,039 -1.92% 219,700
26/06/24 2,079 +0.97% 234,900
25/06/24 2,059 +12.45% 246,400
24/06/24 1,831 -0.11% 19,800

Delayed Quote Japan Exchange, June 28, 2024 at 07:00 am

More quotes
Kohjin Bio Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of bacterial testing media, in vitro diagnostic drugs, cell culture media, as well as contract cell processing. The Company operates through three segments. The Tissue Culture business segment develops, manufactures, and sells tissue culture media, including serum-free media used for research purposes in regenerative medicine and immunotherapy. The Microbiology business segment develops, manufactures, and sells a wide variety of microorganism detection media used for pathogen testing in the clinical and food fields, and quality testing in various fields such as pharmaceuticals and cosmetics. The Cell Processing business segment conducts cell processing operations under contract from medical institutions at facilities that have obtained permission to manufacture specified cell products based on the Regenerative Medicine Safety Act.
More about the company

Annual profits - Rate of surprise